Published in Lab Law Weekly, August 19th, 2005
The company, using its patent pending solid lipid nanoparticle delivery platform, is developing three antibiotic products: Rifamsolin, Zysolin and Ocusolin, targeting the treatment of tuberculosis, hospital acquired pneumonia (HAP) and ocular infection respectively.
The company's regulatory strategy for these products is to focus on obtaining market entry as quickly as possible. One part of the strategy is to seek approval...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.